This is a significant positive catalyst for SMMT. The strong OS data from HARMONi-2 de-risks the ivonescimab program and supports the ongoing HARMONi-7 global study. Traders should watch for the full data presentation at WCLC on September 15, 2026, and the upcoming PDUFA date of November 14, 2026 for the HARMONi BLA. The stock may see upward momentum as the market prices in improved probability of success for ivonescimab in the first-line NSCLC setting.
Price Chart
Executive Summary
Summit Therapeutics announced via 8-K that its partner Akeso presented updated overall survival (OS) data from the Phase III HARMONi-2 trial of ivonescimab vs. pembrolizumab in PD-L1-positive advanced NSCLC at WCLC 2026. Ivonescimab demonstrated a statistically significant 27% reduction in the risk of death (HR 0.73, p=0.009) with a median OS improvement of 8.2 months (30.8 vs 22.6 months), including a strong HR of 0.58 in the PD-L1 high subgroup. This is a major positive catalyst for Summit's ivonescimab program and supports the ongoing global Phase III HARMONi-7 study, though ivonescimab remains unapproved in Summit's license territories (US, Europe).
Key Facts
- Ivonescimab reduced risk of death by 27% vs pembrolizumab (HR 0.73; 95% CI 0.57-0.95; p=0.009) in HARMONi-2 Phase III trial.
- Median OS was 30.8 months for ivonescimab vs 22.6 months for pembrolizumab, an 8.2-month improvement.
- In PD-L1 high expression subgroup (score ≥50%), HR was 0.58 (95% CI 0.38-0.89).
- HARMONi-2 is the fourth Phase III study of ivonescimab to show statistically significant improvements in both OS and PFS vs standard of care.
- Summit is conducting the global Phase III HARMONi-7 study (target 780 patients) evaluating ivonescimab monotherapy vs pembrolizumab in PD-L1 high-expressing metastatic NSCLC.
- Ivonescimab remains investigational and not approved by any regulatory authority in Summit's license territories (US, Europe).
- Akeso received NMPA marketing authorization in China for ivonescimab based on HARMONi-2 results in April 2025.
- Summit's BLA for ivonescimab in EGFR-mutated NSCLC (HARMONi study) was accepted by FDA with PDUFA date of November 14, 2026.
Financial Impact
No financial figures reported in filing. Positive OS data strengthens ivonescimab's commercial prospects and supports Summit's $14B market cap. Key catalyst for HARMONi-7 global study and potential US/EU regulatory filings.
Risk Factors
- Ivonescimab is not yet approved in US or Europe; regulatory risk remains.
- HARMONi-2 was a single-region (China) study; global HARMONi-7 results may differ.
- Competition from existing PD-1 inhibitors and other bispecific antibodies in development.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001599298-26-000078 |
| Document: a2026_prx0913xharmoni-2o.htm | 0001599298-26-000078 |
| Document: 0001599298-26-000078-index-headers.html | 0001599298-26-000078 |
| Document: 0001599298-26-000078-index.html | 0001599298-26-000078 |
| Document: 0001599298-26-000078.txt | 0001599298-26-000078 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | 8-K | $17.40 $17.85 | ▲ +2.59% | ▲ +1.77% | $16.75 (−3.71%) |
Sep 14, 2026 18d ago | 8-K | $18.42 $16.90 | ▼ −8.25% | ▼ −8.36% | $16.75 (−9.04%) |
Sep 3, 2026 29d ago | 8-K | $17.13 $17.55 | ▲ +2.45% | ▲ +3.60% | $16.75 (−2.19%) |
Aug 26, 2026 5w ago | 8-K | $14.23 $14.60 | ▲ +2.60% | ▲ +2.72% | $16.75 (+17.74%) |
Aug 5, 2026 8w ago | 8-K | $13.53 $15.10 | ▲ +11.60% | ▲ +11.25% | $16.75 (+23.84%) |
Jul 22, 2026 10w ago | 8-K | $14.74 $12.80 | ▼ −13.16% | ▼ −10.76% | $16.75 (+13.67%) |
Jun 12, 2026 16w ago | Insider Cluster | $14.01 $13.75 | ▼ −1.86% | ▼ −2.53% | $16.75 (+19.59%) |
Jun 12, 2026 16w ago | Institutional Cluster | $14.01 $13.75 | ▼ −1.86% | ▼ −2.53% | $16.75 (+19.59%) |
Jun 11, 2026 16w ago | Institutional Cluster | $13.08 $14.07 | ▲ +7.57% | ▲ +7.14% | $16.75 (+28.10%) |
Jun 9, 2026 16w ago | S-3ASR | $13.05 $13.88 | ▼ −6.36% | ▼ −2.93% | $16.75 (−28.39%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access